Latest News
News Functions
Additional Functions
11 July 2024
VALBIOTIS SA
Valbiotis : Bilan semestriel du contrat de liquidité
5 July 2024
VALBIOTIS SA
Valbiotis : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – Juin 2024
26 June 2024
VALBIOTIS SA
Valbiotis – Assemblée générale annuelle mixte du 25 juin 2024
20 June 2024
VALBIOTIS SA
Valbiotis : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – Mai 2024
17 June 2024
VALBIOTIS SA
Valbiotis invited to present clinical results at the American Diabetes Association’s 84th Scientific Sessions
4 June 2024
VALBIOTIS SA
Valbiotis reaches an agreement to terminate its licensing and supply agreement with Nestlé Health Science
24 May 2024
VALBIOTIS SA
Valbiotis : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – 17 mai 2024
22 May 2024
VALBIOTIS SA
Valbiotis launches its e-commerce site for the marketing of Valbiotis®PRO Cholestérol
14 May 2024
VALBIOTIS SA
Valbiotis : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
26 April 2024
VALBIOTIS SA
Valbiotis publishes its annual accounts 2023
8 April 2024
VALBIOTIS SA
Valbiotis : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – Mars 2024
3 April 2024
VALBIOTIS SA
Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May
7 March 2024
VALBIOTIS SA
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – Février 2024
6 February 2024
VALBIOTIS SA
Valbiotis : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
30 January 2024
VALBIOTIS SA
Valbiotis : Bilan du contrat de liquidité pour le deuxième semestre 2023
29 January 2024
VALBIOTIS SA
Valbiotis presents its 2024 financial communication calendar
16 January 2024
VALBIOTIS SA
Valbiotis sets out its commercial and clinical roadmap for 2024
9 January 2024
VALBIOTIS SA
Valbiotis : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – Décembre 2023
22 December 2023
VALBIOTIS SA
Valbiotis announces the success of its €15 M capital increase
11 December 2023
VALBIOTIS SA
Valbiotis announces the launch of a capital increase
VALBIOTIS SA
Valbiotis announces the availability of an amendment to the Universal Registration Document
VALBIOTIS SA
Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status
4 December 2023
VALBIOTIS SA
VALBIOTIS SA:
7 November 2023
VALBIOTIS SA
Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
6 November 2023
VALBIOTIS SA
Valbiotis : Déclaration mensuelle du nombre d’actions et droits de vote – Octobre 2023
4 October 2023
VALBIOTIS SA
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
2 October 2023
VALBIOTIS SA
VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes
28 September 2023
VALBIOTIS SA
Valbiotis publishes its financial report for the first half of 2023 and confirms its strategic roadmap
11 September 2023
VALBIOTIS SA
VALBIOTIS SA: Valbiotis presents the full results of the Phase II/III REVERSE-IT study: impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes
6 September 2023
VALBIOTIS SA
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – Juillet 2023